TY - JOUR
T1 - 3D Bioprinted Multicellular Vascular Models
AU - Gold, Karli A.
AU - Saha, Biswajit
AU - Rajeeva Pandian, Navaneeth Krishna
AU - Walther, Brandon K.
AU - Palma, Jorge A.
AU - Jo, Javier
AU - Cooke, John P.
AU - Jain, Abhishek
AU - Gaharwar, Akhilesh K.
N1 - Funding Information:
The authors acknowledge Dr. Rola Barhoumi Mouneimne of the Texas A&M Veterinary Medicine and Biomedical Sciences Image Analysis Lab for her assistance with multiphoton imaging of printed constructs. The authors would also like to acknowledge the Texas A&M University Veterinary Medicine and Biomedical Sciences CVM Histology Lab for their assistance performing histology. Some of the schematics are draw using Biorender.com. K.G. acknowledges financial support from Texas A&M University Graduate Diversity fellowship. The authors would like to acknowledge financial support from Texas A&M Engineering Experiment Station (TEES), the National Institute of Biomedical Imaging and Bioengineering (NIBIB) (DP2 EB026265 to A.K.G. and R21 EB025945 to A.J), the National Science Foundation (CBET 1705852 and 1944322), and the Office of the President at Texas A&M University for X‐Grant and T3 (to both A.K.G. and A.J.). J.P.C. acknowledges support from the National Heart Lung and Blood Institute, 1R01HL148338, 1R01HL133254, HL133254, and 1R01HL157790.
Funding Information:
The authors acknowledge Dr. Rola Barhoumi Mouneimne of the Texas A&M Veterinary Medicine and Biomedical Sciences Image Analysis Lab for her assistance with multiphoton imaging of printed constructs. The authors would also like to acknowledge the Texas A&M University Veterinary Medicine and Biomedical Sciences CVM Histology Lab for their assistance performing histology. Some of the schematics are draw using Biorender.com. K.G. acknowledges financial support from Texas A&M University Graduate Diversity fellowship. The authors would like to acknowledge financial support from Texas A&M Engineering Experiment Station (TEES), the National Institute of Biomedical Imaging and Bioengineering (NIBIB) (DP2 EB026265 to A.K.G. and R21 EB025945 to A.J), the National Science Foundation (CBET 1705852 and 1944322), and the Office of the President at Texas A&M University for X-Grant and T3 (to both A.K.G. and A.J.). J.P.C. acknowledges support from the National Heart Lung and Blood Institute, 1R01HL148338, 1R01HL133254, HL133254, and 1R01HL157790.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
PY - 2021/11/3
Y1 - 2021/11/3
N2 - 3D bioprinting is an emerging additive manufacturing technique to fabricate constructs for human disease modeling. However, current cell-laden bioinks lack sufficient biocompatibility, printability, and structural stability needed to translate this technology to preclinical and clinical trials. Here, a new class of nanoengineered hydrogel-based cell-laden bioinks is introduced, that can be printed into 3D, anatomically accurate, multicellular blood vessels to recapitulate both the physical and chemical microenvironments of native human vasculature. A remarkably unique characteristic of this bioink is that regardless of cell density, it demonstrates a high printability and ability to protect encapsulated cells against high shear forces in the bioprinting process. 3D bioprinted cells maintain a healthy phenotype and remain viable for nearly one-month post-fabrication. Leveraging these properties, the nanoengineered bioink is printed into 3D cylindrical blood vessels, consisting of living co-culture of endothelial cells and vascular smooth muscle cells, providing the opportunity to model vascular function and pathophysiology. Upon cytokine stimulation and blood perfusion, this 3D bioprinted vessel is able to recapitulate thromboinflammatory responses observed only in advanced in vitro preclinical models or in vivo. Therefore, this 3D bioprinted vessel provides a potential tool to understand vascular disease pathophysiology and assess therapeutics, toxins, or other chemicals.
AB - 3D bioprinting is an emerging additive manufacturing technique to fabricate constructs for human disease modeling. However, current cell-laden bioinks lack sufficient biocompatibility, printability, and structural stability needed to translate this technology to preclinical and clinical trials. Here, a new class of nanoengineered hydrogel-based cell-laden bioinks is introduced, that can be printed into 3D, anatomically accurate, multicellular blood vessels to recapitulate both the physical and chemical microenvironments of native human vasculature. A remarkably unique characteristic of this bioink is that regardless of cell density, it demonstrates a high printability and ability to protect encapsulated cells against high shear forces in the bioprinting process. 3D bioprinted cells maintain a healthy phenotype and remain viable for nearly one-month post-fabrication. Leveraging these properties, the nanoengineered bioink is printed into 3D cylindrical blood vessels, consisting of living co-culture of endothelial cells and vascular smooth muscle cells, providing the opportunity to model vascular function and pathophysiology. Upon cytokine stimulation and blood perfusion, this 3D bioprinted vessel is able to recapitulate thromboinflammatory responses observed only in advanced in vitro preclinical models or in vivo. Therefore, this 3D bioprinted vessel provides a potential tool to understand vascular disease pathophysiology and assess therapeutics, toxins, or other chemicals.
KW - 3D bioprinting
KW - cell-laden bioink
KW - disease models
KW - regenerative medicine
KW - vascular tissue
KW - Tissue Scaffolds
KW - Bioprinting
KW - Endothelial Cells
KW - Humans
KW - Printing, Three-Dimensional
KW - Tissue Engineering
UR - http://www.scopus.com/inward/record.url?scp=85111694775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111694775&partnerID=8YFLogxK
U2 - 10.1002/adhm.202101141
DO - 10.1002/adhm.202101141
M3 - Article
C2 - 34310082
AN - SCOPUS:85111694775
SN - 2192-2640
VL - 10
SP - e2101141
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 21
M1 - 2101141
ER -